"Watchful waiting" after thrombolysis: It's time for a re-evaluation

Journal of the American College of Cardiology

Volumn 42, Issue 1, 2003, Pages 17-19

  O'Neill, William W ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; HEART ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRIDINE DERIVATIVE;

ANALGESIA; BLOOD CLOT LYSIS; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DILATATION; CORONARY STENT; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HEALTH INSURANCE; HEART CATHETERIZATION; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART MUSCLE REVASCULARIZATION; HEART REINFARCTION; HUMAN; ISCHEMIA; MORTALITY; NOTE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RECURRENT DISEASE; RIGHT CORONARY ARTERY; SIDE EFFECT; ST SEGMENT ELEVATION; SURGICAL TECHNIQUE; THORAX PAIN; TREATMENT OUTCOME;

EID: 0037868146     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00507-2     Document Type: Editorial

References (27)

1. Smith SC Jr., for ACC/AHA Task Force Committee. ACA/AHA Practice guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines). A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 2002;37:2239i-lxvi.
2. Van de Werf F, Ardissino D, Betriu A, et al., for The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003;24:28-66.
3. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 2000;36:2056-63.
4. Morrow DA, Antman EM, Parsons L, et al. Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. JAMA 2001;286:1356-9.
5. Pilote L, Miller DP, Califf RM, Rao JS, Weaver WD, Topol EJ. Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med 1997;335:1198-205.
6. Gibson CM, Karha J, Murphy SA, et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis In Myocardial Infarction trials. J Am Coll Cardiol 2003;42:7-16.
7. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-8.
8. Rogers WJ, Baim DS, Gore JM, et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis In Myocardial Infarction (TIMI) Phase IIA Trial. Circulation 1990;81:1457-76.
9. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
10. SWIFT (Should We Intervene Following Thrombolysis?) Trial Study Group. SWIFT trial of delayed elective intervention v conservative treatment after thrombolysis with anistreplase in acute myocardial infarction. BMJ 1991;302:555-60.
11. Barbash GI, Roth A, Hod H, et al. Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:538-45.
12. Grines CL. Angioplasty in the patient with acute myocardial infarction. In: Roubin GS, Califf RM, O'Neill WW, Phillips HR III, Stack RS, editors. Interventional Cardiovascular Medicine: Principles and Practice. New York, NY: Churchill Livingstone, 1994:253-63.
13. McCullough PA, O'Neill WW, Graham M, et al. A prospective randomized trial of triage angiography in acute coronary syndromes ineligible for thrombolytic therapy. Results of the Medicine versus Angiography in Thrombolytic Exclusion (MATE) Trial. J Am Coll Cardiol 1998;32:596-605.
14. Cannon CP, Weintraub WS, Demopoulos LA, Robertson DH, Gormley GJ, Braunwald E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction. Am J Cardiol 1998;82:731-6.
15. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. FRISC II prospective randomized multicentre study. Invasive compared with non-invasive treatment in unstable coronary-artery disease. Lancet 1999;354:708-15.
16. Fox KAA, Poole-Wilson PA, Clayton TC, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized Intervention Trial of unstable Angina. Lancet 2002;360:743-51.
17. Anderson HV, Cannon CP, Stone PH, et al. One-year results of the Thrombolysis In Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q-wave myocardial infarction. J Am Coll Cardiol 1995;26:1643-50.
18. Boden WE, O'Rourke RA, Crawford MH, et al. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. N Engl J Med 1998;338:1785-92.
19. O'Neill WW, Weintraub R, Grines CL, et al. A prospective, placebo-controlled, randomized trial of intravenous streptokinase and angioplasty versus lone angioplasty therapy of acute myocardial infarction. Circulation 1992;86:1710-7.
20. Madsen JK, Grande P, Saunamaki K, et al. Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. Circulation 1997;96:748-55.
21. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-62.
22. Suh WW, Grill DE, Rihal CS, Bell MR, Hollmes DR Jr., Garratt KN. Unrestricted availability of intracoronary stents is associated with decreased abrupt vascular closure rates and improved early clinical outcomes. Catheter Cardiovasc Interv 2002;55:294-302.
23. O'Neill WW. TEC in acute ischemic syndromes. J Invasive Cardiol 1995;7 Suppl D:4D-9D.
24. Grube E, Gerckens U, Yeung AC. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 2001;104:2436-41.
25. Yarlagadda RK, Boden WE. Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes. Are we all becoming "interventional" cardiologists? J Am Coll Cardiol 2002;40:1915-8.
26. Waters DD, Schwartz GG, Olsson AG, et al. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation 2002;106:1690-5.
27. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.